ICON plc is a global provider of clinical development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development. With headquarters in Dublin, Ireland, ICON currently, operates from 84 locations in 38 countries and has approximately 12,300 employees.
Further information is available at www.iconplc.com.
Kunming Biomed International (KBI) is a world leading CRO providing preclinical research services that specialized in nonhuman primates (NHPs). Led by an experienced international team, KBI has collaborated with over 18 large pharmas using translational NHP models for pharmacological efficacy and safety evaluations, including NASH/fibrosis, diabetes and diabetic complications (nephropathy, retinopathy), and cardiovascular diseases (dyslipidemia, heart failure), etc. KBI has state-of-the-art AAALAC accredited animal research facilities, and extensive colonies (>6000) of healthy and diseased models.
Genuity Science is a wholly-owned subsidiary of US biotechnology company, HiberCell. Genuity Science is using world-leading genomics and machine learning to map the causal biology of disease and accelerate the development of better medicine. Our unique hybrid platform enables us and our partners to go from data to insights to impact with unrivaled power and efficiency, generating, validating and applying insights on virtually any disease to create novel drugs, diagnostics and tools for clinical care. Our capabilities span deeply phenotyped population genomics cohorts, CAP-accredited sequencing and comprehensive omics, world-renowned bioinformatics, and pioneering, validated and peer-reviewed AI/ML. Through our offices in Boston, Dublin and Reykjavik, we put this platform to work for our global biopharma and life sciences partners and the patients they serve.
HepQuant-SHUNT, -STAT, and -FLOW are sensitive, reproducible, accurate, and minimally-invasive tests of global liver function and physiology. They target not only the liver but also the portal circulation and generate a Disease Severity Index (DSI), which ranges from 0 (healthy) to 50 (severe liver disease). DSI may be used for measuring severity of liver disease, tracking disease progression, and monitoring treatment effects. HepQuant’s services include study design, training, consultation, Test Kits, and Laboratory Analyses.
Sonic Incytes Medical Corp. is the developer of VelacurTM – the first handheld 3D liver health assessment solution. Cleared by the FDA, VelacurTM is a breakthrough, non-invasive imaging test that quantifies liver fat and fibrosis with reliability and accuracy comparable to MRI. VelacurTM offers providers a fast, accurate and practical way to measure a patient’s liver health and grow their practice. In addition, it is a cost-effective tool for pharma to screen patients for NASH clinical trials and monitor therapeutic effectiveness of promising NASH drugs..
Syneos Health® is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 27,000 clinical and commercial minds to help our biopharmaceutical customers shorten the distance from lab to life.
Nordic Bioscience has more than 25 years’ experience in biomarker development and integrating these biomarkers into clinical trials with extensive scientific expertise in the fields of fibrosis, rheumatology, immunology and oncology.
Using our unique biomarker technology, we identify predictive and prognostic biomarkers which are used to enrich clinical trials and may reduce trial length and size required to determine therapeutic efficacy.
With over 500 publications in leading journals, we pride ourselves with our highly scientific approach and mindset.
Antaros Medical is pioneering imaging methods, using MRI* and PET**, to both design and deliver clinical imaging studies. Applied with our extensive experience and expertise in drug development and disease biology, our tailored solutions have helped our customers to solve complex problems to empower confident decision-making at every stage of clinical drug development, from small mechanistic studies to large scale studies. Disease areas: CV, renal & metabolic diseases and oncology.
* magnetic resonance imaging
**positron emission tomography
Summit is an Integrated Research Organization that delivers a full spectrum of study enrollment and site enrichment services within our network.
The Summit network consists of experienced research sites that have proven successful in NASH research. With over two decades of experience in conducting, managing, and sourcing clinical research, Summit Clinical Research leadership has the skill set to help sites avoid research pitfalls, strategically improve efficiencies, and most importantly, hit the enrollment goal for targeted clinical trials in an expedited timeline, without compromising patient safety or data quality. To learn more visit, www.summitclinicalresearch.com
PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine. To learn more, visit pathai.com
Together with Key-Opinion-Leaders, Biocellvia has been refining the gold-standards for the analysis of NASH histology. By delivering fully automated quantification of the same features a pathologist would use to determine the NAS score, Biocellvia brings accurate and precise data from across the whole liver section. This precision gives researchers unparalleled confidence in their results and enables better decision making. Not only is the data accurate and precise, but it is also available within 48 hours.
Lightspeed Microscopy accelerates drug development and improves clinical diagnostics by transforming the field of pathology from 2D and slide-based to 3D and digital. Lightspeed has a full stack solution with proprietary sample preparation, patented open-top light-sheet microscopy, and AI analysis. Multiple Pharma companies are using Lightspeed's 3D pathology product to accelerate their pre-clinical drug development through better understanding of mechanisms of action and biodistribution of their lead compounds..
Continuum Clinical is a global clinical trial enrollment company. With over twenty-five years of experience, Continuum Clinical specializes in providing sponsors and CROs with patient recruitment and retention planning, study and site support, patient recruitment campaigns, patient advocacy and diversity & inclusion services, retention solutions, and reporting and analytics.
GD3 (Genesis Drug Discovery & Development) provides contract services to advance NASH research. All areas of preclinical drug discovery and development are supported including:
- DMPK/in-vivo Pharmacology and Toxicology
- Synthetic, Medicinal and Process Chemistry (including IND and IP support)
- Discovery Biology, Hit to Lead and Lead Optimization
- Assay and Biomarker development
GD3’s capabilities and expertise also expand to cover a wide range of therapeutic areas including metabolic diseases, oncology, inflammation, autoimmunity and ophthalmology.
Celerion, a leader in early clinical research services and clinical bioanalysis, is a global company with over 40 years of experience. While having capabilities across multiple therapeutics, we have over a decade of expertise in metabolic diseases. Our comprehensive knowledge of specialized metabolic testing methods and hands-on operational experience enable us to provide outstanding support from First in Human through Proof-of-Concept in the development of diabetes, obesity, NAFLD/NASH and cardio-metabolic interventions.
Aragen Bioscience is a world leader in accelerating preclinical respiratory disease and fibrosis research. With more than 500 fibrosis focused studies under our belt, our strengths lie in translational in vivo modelling of a variety of fibrotic diseases including pulmonary fibrosis. We have combined our strength in IPF with our strength in infectious diseases to help understand potential links between IPF and infectious respiratory diseases. We have perfected the measurement of parameters such as flexiVent™; whole-body plethysmography; and hypoxia-related parameters in our animal models and have supported these measurements with a broad suite of biomarkers of respiratory pathophysiology, disease progression, and treatment. We are based in the San Francisco Bay area.
Discover what our 2019 partners thought of the event: